Date: 2011-12-02
Type of information: Development agreement
Compound: daclatasvir (BMS-790052),TMC435 (The drug has been jointly developed by Medivir and Tibotec Pharmaceuticals)
Company: BMS (USA) Tibotec Pharmaceuticals-J&J (Ireland - USA)
Therapeutic area: Infectious diseases
Type agreement: Clinical collaboration
Development
Action mechanism:
Disease: patients with genotype 1 hepatitis C virus
Details: BMS has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical Companies, to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
Under the agreement the companies will evaluate the potential to achieve sustained viral response 12 and 24 weeks post treatment in patients with HCV genotype 1 in a study with three treatment regimens: an oral, once-daily treatment regimen of daclatasvir and TMC435 with pegylated-interferon alpha plus ribavirin; an oral, once-daily treatment regimen of daclatasvir and TMC435 with ribavirin and an oral, once-daily treatment regimen of daclatasvir and TMC435 alone. The study is planned to start in the first half of 2012.
Financial terms:
Latest news:
